[1]
|
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志(中英文), 2018, 2(4): 196-225.
|
[2]
|
Mcmurray, J.J., Packer, M., Desai, A.S., et al. (2014) Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. The New England Journal of Medicine, 371, 993-1004. https://doi.org/10.1056/NEJMoa1409077
|
[3]
|
Mcdonagh, T.A., Metra, M., Adamo, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. https://doi.org/10.1093/eurheartj/ehab368
|
[4]
|
Almufleh, A., Marbach, J., Chih, S., et al. (2017) Ejection Fraction Improvement and Reverse Remodeling Achieved with Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients. American Journal of Cardiovascular Disease, 7, 108-113.
|
[5]
|
Desai, A.S., Solomon, S.D., Shah, A.M., et al. (2019) Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 322, 1077-1084.
https://doi.org/10.1001/jama.2019.12843
|
[6]
|
Bayard, G., Da Costa, A., Pierrard, R., et al. (2019) Impact of Sacubitril/Valsartan on Echo Parameters in Heart Failure Patients with Reduced Ejection Fraction a Prospective Evaluation. International Journal of Cardiology Heart & Vasculature, 25, Article ID: 100418. https://doi.org/10.1016/j.ijcha.2019.100418
|
[7]
|
Inohara, T., Kim, S., Pieper, K., et al. (2019) B-Type Natriuretic Peptide, Disease Progression and Clinical Outcomes in Atrial Fibrillation. Heart, 105, 370-377.
|
[8]
|
Devereux, R.B., Alonso, D.R., Lutas, E.M., et al. (1986) Echocardiographic Assessment of Left Ventricular Hypertrophy: Comparison to Necropsy Findings. The American Journal of Cardiology, 57, 450-458.
https://doi.org/10.1016/0002-9149(86)90771-X
|
[9]
|
Januzzi, J.L., Prescott, M.F., Butler, J., et al. (2019) Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients with Heart Failure With Reduced Ejection Fraction. JAMA, 322, 1085-1095. https://doi.org/10.1001/jama.2019.12821
|
[10]
|
Solomon, S.D., Zile, M., Pieske, B., et al. (2012) The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase 2 Double-Blind Randomised Controlled Trial. The Lancet, 380, 1387-1395. https://doi.org/10.1016/S0140-6736(12)61227-6
|
[11]
|
Wachter, R., Senni, M., Belohlavek, J., et al. (2019) Initiation of Sacubitril/Valsartan in Haemodynamically Stabilised Heart Failure Patients in Hospital or Early after Discharge: Primary Results of the Randomised TRANSITION Study. European Journal of Heart Failure, 21, 998-1007.
|
[12]
|
Singh, J.S.S., Burrell, L.M., Cherif, M., et al. (2017) Sacubitril/Valsartan: Beyond Natriuretic Peptides. Heart, 103, 1569-1577. https://doi.org/10.1136/heartjnl-2017-311295
|
[13]
|
Zile, M.R., O’Meara, E., Claggett, B., et al. (2019) Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients with HFrEF. Journal of the American College of Cardiology, 73, 795-806.
https://doi.org/10.1016/j.jacc.2018.11.042
|
[14]
|
Iborra-Egea, O., Gálvez-Montón, C., Roura, S., et al. (2017) Mechanisms of Action of Sacubitril/Valsartan on Cardiac Remodeling: A Systems Biology Approach. NPJ Systems Biology and Applications, 3, Article No. 12.
https://doi.org/10.1038/s41540-017-0013-4
|
[15]
|
Villani, A., Ravaro, S., Cerea, P., et al. (2020) Do the Remodeling Effects of Sacubitril/Valsartan Treatment Depend upon Heart Failure Duration? Journal of Cardiovascular Medicine, 21, 682-687.
https://doi.org/10.2459/JCM.0000000000001000
|
[16]
|
Mcmurray, J.J.V., Jackson, A.M., Lam, C.S.P., et al. (2020) Effects of Sacubitril-Valsartan versus Valsartan in Women Compared with Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation, 141, 338-351. https://doi.org/10.1161/CIRCULATIONAHA.119.044491
|
[17]
|
Paolini, C., Mugnai, G., Dalla Valle, C., et al. (2021) Effects and Clinical Implications of Sacubitril/Valsartan on Left Ventricular Reverse Remodeling in Patients Affected by Chronic Heart Failure: A 24-Month Follow-Up. International Journal of Cardiology Heart & Vasculature, 35, Article ID: 100821. https://doi.org/10.1016/j.ijcha.2021.100821
|
[18]
|
Landolfo, M., Piani, F., Esposti, D.D., et al. (2020) Effects of Sacubitril Valsartan on Clinical and Echocardiographic Parameters of Outpatients with Heart Failure and Reduced Ejection Fraction. International Journal of Cardiology Heart & Vasculature, 31, Article ID: 100656. https://doi.org/10.1016/j.ijcha.2020.100656
|
[19]
|
Gu, W., Xu, C., Li, Z., et al. (2021) Echocardiographic Changes in Elderly Patients with Heart Failure with Reduced Ejection Fraction after Sacubitril-Valsartan Treatment. Cardiovascular Diagnosis and Therapy, 11, 1093-1100.
|
[20]
|
Mendelsohn, M.E. and Karas, R.H. (1999) The Protective Effects of Estrogen on the Cardiovascular System. The New England Journal of Medicine, 340, 1801-1811. https://doi.org/10.1056/NEJM199906103402306
|
[21]
|
Simoncini, T., Genazzani, A.R. and Liao, J.K. (2002) Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene. Circulation, 105, 1368-1373.
https://doi.org/10.1161/hc1102.105267
|
[22]
|
Baltatu, O., Cayla, C., Iliescu, R., et al. (2003) Abolition of End-Organ Damage by Antiandrogen Treatment in Female Hypertensive Transgenic Rats. Hypertension, 41, 830-833. https://doi.org/10.1161/01.HYP.0000048702.55183.89
|
[23]
|
Cavasin, M.A., Tao, Z.Y., Yu, A.L., et al. (2006) Testosterone Enhances Early Cardiac Remodeling after Myocardial Infarction, Causing Rupture and Degrading Cardiac Function. American Journal of Physiology Heart and Circulatory Physiology, 290, H2043-H2050.
|
[24]
|
Planavila, A., Laguna, J.C. and Vázquez-Carrera, M. (2005) Nuclear Factor-KappaB Activation Leads to Down-Regulation of Fatty Acid Oxidation during Cardiac Hypertrophy. The Journal of Biological Chemistry, 280, 17464-17471.
https://doi.org/10.1074/jbc.M414220200
|